+0.55%
Today
Loading 1D prices…
Company profile
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Calabasas, CA, United States
Employees
5
Fiscal year end
1231
CIK
1979414
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BGMBGM Group Ltd. Class A Ordinary Shares | $105.4M | $37.9M | -52.59% | -$0.18 | -4.71% | Unrated |
| COYACoya Therapeutics Inc. Common Stock | $102.7M | $7.9M | -267.14% | -$1.27 | -3.10% | Buy |
| PLYXPolaryx Therapeutics Inc. Common Stock | $100.2M | $0.00 | — | -$0.20 | +1.01% | Buy |
| AARDAardvark Therapeutics Inc. Common Stock | $112.3M | $0.00 | — | -$2.93 | +2.40% | Hold |
| QUCYQuantum Cyber N.V. Ordinary Shares | $112.7M | $537.1K | -3018.31% | -$2.70 | -1.46% | Hold |